CPT Code Q9967: A Deep Dive into Low-Osmolar Contrast Media and Its Place in Modern Medical Coding

In the intricate world of modern medicine, clarity is not a luxury—it is a necessity. For decades, physicians peered into the human body through a glass, darkly, relying on X-rays that revealed the stark architecture of bones but left the delicate tapestry of soft tissues, vessels, and organs shrouded in ambiguity. Then came a revolution, an agent of illumination that transformed diagnostic imaging from an art of inference into a science of precision: contrast media.

This article focuses on one specific, crucial identifier in the vast universe of medical coding: CPT Code Q9967. To the uninitiated, it is merely an alphanumeric sequence buried in a dense fee schedule. But to radiologists, cardiologists, medical coders, and healthcare administrators, Q9967 represents much more. It is the code for “Low-osmolar contrast material, 200-299 mg/ml iodine concentration, per ml,” a fundamental building block for billing the contrast agents that make millions of CT angiographies, urograms, and other advanced scans possible. This code is a gateway to understanding not just reimbursement, but patient safety, technological advancement, and the complex interplay between clinical practice and administrative finance. We will embark on a detailed exploration of this code, dissecting its clinical context, its precise application, and its critical role in the sustainable function of diagnostic medicine.

Demystifying the Q-Code: What Exactly is CPT Code Q9967?

First, it is essential to understand what a “Q-code” is. The Healthcare Common Procedure Coding System (HCPCS) is divided into two levels:

• Level I: Current Procedural Terminology (CPT®) codes, maintained by the American Medical Association (AMA), which describe procedures and services (e.g., 74177 for a CT abdomen with contrast).

• Level II: National codes used to identify products, supplies, and services not included in the CPT code set. These include codes for ambulance services, durable medical equipment, drugs, and other items. They are alphanumeric, starting with a letter (A to V) followed by four numbers.

Q9967 falls under Level II of HCPCS. The “Q” prefix is specifically used for temporary codes assigned for a variety of purposes, including drugs and biologicals. Unlike CPT codes, which are typically updated annually, Q-codes can be introduced, changed, or discontinued more frequently by the Centers for Medicare & Medicaid Services (CMS).

Therefore, HCPCS Code Q9967 is defined as:
“Low-osmolar contrast material, 200-299 mg/ml iodine concentration, per ml.”

Let’s break down this definition:

• Low-osmolar contrast material (LOCM): This specifies the type of contrast agent. Osmolarity refers to the number of particles in a solution. LOCM is a newer generation of contrast media that is safer, particularly for high-risk patients.

• 200-299 mg/ml iodine concentration: This is the critical concentration range. Iodine is the radio-opaque element that absorbs X-rays and creates the “contrast” or whiteness on the image. This code is used for contrast agents where each milliliter (ml) of liquid contains between 200 and 299 milligrams (mg) of iodine.

• Per ml: This indicates that the code is billed for each milliliter of contrast administered to the patient. This is a supply code, not a procedure code.

3. The Clinical Significance of Contrast Media: Why It Matters

Contrast media are not merely dyes; they are sophisticated pharmaceutical agents designed to alter how tissues interact with energy from imaging equipment.

How Contrast Media Works:
Iodine has a high atomic number (53), which means it has a high density of electrons. When X-rays or CT beams pass through the body, tissues with higher atomic numbers (like iodine) absorb significantly more radiation than surrounding soft tissues (composed of elements with lower atomic numbers like hydrogen, carbon, and oxygen). This differential absorption creates a stark white appearance on the resulting image, allowing radiologists to distinguish between blood vessels and other structures, identify leaks, highlight tumors, and visualize inflammation.

Key Clinical Applications Enabled by LOCM (Q9967):

• Computed Tomography (CT) Angiography: Visualizing arterial and venous systems throughout the body (e.g., coronary arteries, pulmonary arteries, carotid arteries, aorta).

• CT Urography: Evaluating the kidneys, ureters, and bladder for stones, tumors, or obstructions.

• Oncologic Imaging: Detecting, characterizing, and monitoring the response to therapy of tumors, which often have unique vascular patterns.

• Trauma Imaging: Rapidly identifying active bleeding from injured organs or vessels.

• Neurologic Imaging: Assessing blood-brain barrier breakdown in strokes, tumors, or infections.

Without contrast media, these detailed diagnoses would be impossible, leading to increased invasive procedures, delayed treatments, and poorer patient outcomes.

4. A Tale of Two Contrasts: High-Osmolar vs. Low-Osmolar (HOCM vs. LOCM)

The evolution of contrast media is a story of pursuing patient safety. Understanding the difference between types is key to understanding why Q9967 and its sibling codes exist.

Why LOCM Became the Standard:
The high osmolarity of HOCM caused fluid to shift out of blood vessels and into tissues, which could stress the heart and kidneys. Its ionic nature also increased chemical toxicity and the risk of allergic-like reactions. LOCM, being non-ionic and closer to the osmolarity of blood, is far better tolerated. It is strongly recommended for patients with a history of contrast reaction, asthma, allergies, cardiac or renal disease, and for critical procedures like coronary angiography.

 Common LOCM Agents and Their Concentrations (Examples)

Note: Concentrations are examples; always verify the specific concentration on the vial.

5. The Specifics of Q9967: Dosage, Administration, and Billing Units

The administration of contrast is a precise science. The dose is not arbitrary; it is calculated based on the clinical question, the patient’s weight, and the specific protocol for the scanner.

Typical Dosage Ranges:
For a standard adult CT scan, the dose can range from 75 ml to 150 ml, though this varies widely. A cardiac CTA might use 60-80 ml, while a triple-phase liver CT might use 120-150 ml. The dose is tailored to achieve optimal vascular or parenchymal enhancement.

How Q9967 is Billed:
Q9967 is billed per milliliter of contrast administered. The coding and billing staff must know the exact volume used and the exact concentration of the agent.

Example Calculation:
A patient receives a CT angiography scan. The radiologist uses 100 ml of Iohexol-240 (a common LOCM with a concentration of 240 mgI/mL).

• Concentration: 240 mgI/mL falls squarely within the 200-299 mg/ml range.

• Volume: 100 ml.

• Billing: 100 units of HCPCS code Q9967.

It is a critical responsibility of the radiology department to have a system in place—often integrated with the contrast media power injector and the electronic health record (EHR)—to accurately capture and document this volume.

6. Navigating the Billing Landscape: When and How to Use Q9967

Billing Q9967 is not as simple as just reporting the volume used. It must be billed correctly in relation to the primary procedure code.

1. Billing with the Correct Procedure Code:
Q9967 is a supply code. It must always be billed in conjunction with the appropriate CPT code for the imaging procedure performed (e.g., 71260 for CT chest with contrast, 74175 for CT abdomen with contrast). The procedure code represents the professional and technical component of performing and interpreting the scan; Q9967 represents the cost of the drug supply.

2. Medicare and J-Codes vs. Q-Codes:
It’s important to distinguish between two billing systems for drugs:

• J-Codes (e.g., J-codes for drugs): These are used for drugs that are not furnished “incident to” a physician’s service and are often billed separately in the outpatient hospital setting under the Hospital Outpatient Prospective Payment System (OPPS).

• Q-Codes (e.g., Q9967): These are typically used by physician offices, ambulatory surgical centers (ASCs), and sometimes inpatient settings when billing for the supply of the drug under the Physician Fee Schedule (PFS).

The place of service dictates which code set is appropriate. A physician’s office will bill Q9967 to Medicare. A hospital outpatient department would typically bill for the contrast agent under a separate APC (Ambulatory Payment Classification) using a J-code or another mechanism, not the Q-code. Always follow payer-specific guidelines.

3. Modifiers:
Generally, no modifier is required for Q9967 when billed with a primary procedure code. However, if multiple procedures are performed using contrast on the same day, ensure medical necessity is documented for each.

7. Documentation is King: What Must Be in the Medical Record

Robust documentation is the foundation of accurate coding and defensible billing. The medical record must provide a clear audit trail for the use of Q9967.

Essential Elements to Document:

• Medical Necessity: The reason for the contrast-enhanced study must be clear from the physician’s order and the history.

• Contrast Agent Details: The specific name (e.g., “Iohexol”) and the concentration (e.g., “240 mgI/mL”) must be documented in the report or in the medication administration record (MAR).

• Volume Administered: The exact volume (e.g., “100 mL”) must be recorded. This is often documented by the radiologic technologist administering the dose.

• Route of Administration: Must be documented as “intravenous” (IV).

• Patient Tolerance: Any reaction or statement that the contrast was tolerated without issue should be noted.

An auditor should be able to easily cross-reference the billed units of Q9967 with the documented volume and concentration in the patient’s chart.

8. Common Billing Errors and How to Avoid Them

Mistakes in billing Q9967 can lead to claim denials, delays in payment, or even allegations of fraud.

1. Incorrect Concentration Code: Using Q9967 for a contrast agent with a concentration of 300 mgI/mL is incorrect. That concentration requires Q9957. Using Q9967 for 370 mgI/mL (which requires Q9958) is also an error. Always verify the concentration on the vial used.

2. Billing for Non-Covered Services: Billing for contrast when the primary procedure was denied for medical necessity will also lead to a denial of the Q9967 code.

3. Incorrect Volume Billed: Billing for 150 ml when only 100 ml was administered is a serious error. Ensure the volume documented matches the volume billed.

4. Duplicate Billing: Billing both a Q-code and a J-code for the same service.

5. Billing for Extravasation: If a significant portion of the contrast extravasates (leaks into the tissue) and the diagnostic quality of the scan is compromised, billing for the full volume may be questioned. Documentation must detail the event.

How to Avoid Errors:

• Implement a double-check system where the coder verifies the concentration and volume against the radiology report or MAR.

• Provide ongoing education for radiologic technologists on the importance of precise documentation.

• Utilize EHR systems that automatically pull data from the power injector into the patient’s record.

9. The Financial Impact: Reimbursement Considerations for Q9967

Reimbursement for Q9967 is not a fixed dollar amount; it varies by payer and is often based on the Medicare Physician Fee Schedule’s methodology.

Medicare’s Payment Calculation:
Medicare pays for drugs like contrast media based on a formula derived from the Average Sales Price (ASP) plus a percentage add-on (e.g., ASP + 6%). The ASP is a metric calculated by CMS based on manufacturer-reported sales data.

• Each Q-code has its own assigned HCPCS Payment Allowance based on the ASP of drugs in that category.

• The payment is per unit (per ml). Therefore, the total reimbursement for contrast is [ASP + 6%] * [Volume in ml].

This means the financial impact of using a more expensive LOCM versus an older HOCM is directly reflected in the reimbursement. It also highlights the importance of accurate volume reporting, as it directly affects the supply cost recovery for the practice.

10. Beyond Q9967: Other Contrast Media Codes

Q9967 is part of a family of codes for LOCM. Coders must be aware of the others to ensure accuracy.

• Q9950: Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml. (Less common for IV use, sometimes for other procedures).

• Q9956: Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml. This code was deleted as of January 1, 2024, and replaced by more specific codes.

• Q9957: Low osmolar contrast material, 300-349 mg/ml iodine concentration, per ml. (This is the correct code for common 300 and 320 mgI/mL concentrations).

• Q9958: Low osmolar contrast material, 350-399 mg/ml iodine concentration, per ml. (This is the correct code for 350, 370, and 400 mgI/mL concentrations).

• Q9966: Low osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml.

The deletion of Q9956 and the introduction of more granular codes (Q9957, Q9958, Q9966) underscore the importance of staying current with annual HCPCS updates from CMS.

11. The Future of Contrast Imaging and Coding

The field is not static. Innovations continue to shape both clinical practice and coding.

• Precision Dosing: AI-powered software is being developed to calculate the minimal effective dose of contrast for each individual patient based on body habitus and cardiac output, potentially changing typical volumes.

• New Agents: Development continues on “iso-osmolar” agents and agents with other pharmacological properties (e.g., liver-specific contrast).

• Coding Evolution: The trend toward greater specificity (as seen with the split of Q9956) will likely continue. Coders must commit to lifelong learning.

• Renal Protection: Increased use of pre-procedural hydration protocols and potentially new pharmaceuticals to further reduce the risk of contrast-induced nephropathy.

12. Conclusion

CPT code Q9967 is far more than a billing tool; it is a precise identifier for a critical pharmaceutical agent that enables life-saving diagnostics. Its accurate application hinges on a deep understanding of clinical protocols, meticulous documentation, and vigilant coding practices. Navigating the complexities of concentration ranges, payer-specific rules, and evolving guidelines is essential for ensuring both optimal patient care and the financial integrity of healthcare providers. As medical imaging continues to advance, the role of the informed coder, who can accurately represent the use of agents like low-osmolar contrast media, remains indispensable.

13. Frequently Asked Questions (FAQs)

Q1: Can I bill Q9967 for contrast used in an MRI scan?
A: No, absolutely not. Q9967 and its family of codes are strictly for iodinated contrast media used in X-ray and CT imaging. MRI uses contrast agents based on Gadolinium, which are billed under an entirely different set of HCPCS J-codes (e.g., J0881, J0885, etc.).

Q2: What happens if our facility only uses 350 mgI/mL contrast? Do we ever use Q9967?
A: If you exclusively use a 350 mgI/mL concentration, you would use Q9958 (for 350-399 mg/ml), not Q9967. You would only use Q9967 if you administered a contrast agent from a vial labeled with a concentration between 200 and 299 mgI/mL.

Q3: A patient received 120 ml of contrast, but 20 ml extravasated. Do we bill for 120 ml or 100 ml?
A: This is a complex scenario. The code represents the supply furnished. The drug was dispensed and intended for use. However, if the extravasation was significant and the study was non-diagnostic, requiring a repeat, payers may question billing for the wasted volume. The key is detailed documentation: “100 ml administered IV, 20 ml extravasated. Study was diagnostic.” Consult your payer’s specific policy on wasted drugs.

Q4: Who is responsible for ensuring the correct code is billed—the technologist or the coder?
A: It is a shared responsibility within the revenue cycle. The radiologic technologist is responsible for accurately documenting the drug name, concentration, and volume administered in the medical record. The medical coder is responsible for translating that documentation into the correct HCPCS code. Robust communication and processes between these roles are critical.

14. Additional Resources

To ensure you are using the most current and accurate information, always consult the primary sources:

1. Centers for Medicare & Medicaid Services (CMS):

   • HCPCS Release and Code Sets: https://www.cms.gov/medicare/coding-billing/hcpcs-release-code-sets

   • Medicare Physician Fee Schedule Look-Up Tool: https://www.cms.gov/medicare/physician-fee-schedule/search

2. American Medical Association (AMA):

   • CPT® Professional Edition (Annual Publication): https://www.ama-assn.org/amaone/cpt-current-procedural-terminology

3. American College of Radiology (ACR):

   • ACR Manual on Contrast Media: https://www.acr.org/Clinical-Resources/Contrast-Manual (An essential clinical guide that informs coding decisions).

4. Radiology Business Management Association (RBMA):

   • Offers educational resources and updates on radiology-specific coding and reimbursement issues: https://www.rbma.org/

5. Local Carrier Determinations (LCDs):

   • Always check your Medicare Administrative Contractor’s (MAC’s) website for any Local Coverage Determinations regarding medical necessity for contrast-enhanced studies.

Date: August 27, 2025
Author: The Medical Coding Specialist Team
Disclaimer: This article is intended for informational and educational purposes only. It is not a substitute for professional medical coding, billing, or legal advice. CPT® is a registered trademark of the American Medical Association (AMA). The information herein is based on publicly available guidelines and should be verified with the most current AMA CPT, CMS, and payer-specific manuals and policies. The authors and publishers are not responsible for any errors, omissions, or any consequences resulting from the use of this information.